Kyntra Bio, Inc. (KYNB) income statement
KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.95−0.09 (-4.41%)
Close on Nov 18, 2026Market cap $7.90MP/E 0.0Yield –
Kyntra Bio, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 6.3%
- Operating margin
- -1089.8%
- Net margin
- 3967.8%
- Return on equity, FY2025
- -143.5%
Financial strength
- Current ratio
- 2.69
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 140.5%
Valuation
- P/E ratio
- 0.0
- Price to sales
- 1.71
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?